Hungary

Act XCVIII of 2006 on the safe and economical supply of medicines and medical aids sets the pharmacy ownership rule, tightened by the 2010 to 2011 reforms that reversed the earlier liberalisation. A public pharmacy must be operated by a company in which a pharmacist holds a majority, above 50%, of the ownership stake, and the operating right attaches to the pharmacist personally rather than being freely transferable.

That is a harder constraint than the Czech or Slovak odborný zástupca model, because it is not satisfied by employing a responsible pharmacist. It requires a pharmacist with real equity control. A foreign founder can hold a minority position, contract for services, or supply and service the pharmacy, but cannot own it.

The practical consequence is that Hungary is a partnership market, not an ownership market, and the partner has structural leverage that a Czech or Polish partner does not.

This is the finding that changes how Hungary reads. Hi-Doctor, the visible Hungarian-language GLP-1 telehealth operator, does not issue prescriptions through EESZT. It issues cross-border prescriptions registered in the Spanish REMPE system, the Registro de Profesionales Sanitarios, which are then honoured under the EU cross-border healthcare directive.

That is a deliberate arbitrage of prescriber jurisdiction rather than of dispensing jurisdiction. It sidesteps Hungarian prescriber licensing and the EESZT workflow entirely, and leans on the cross-border recognition framework, which was designed for travelling patients rather than for a domestic telehealth channel.

It is worth being precise about the risk: cross-border prescription recognition is a real legal mechanism, but its use as the primary prescribing channel for a domestic patient population has not, as far as the evidence here goes, been tested by a Hungarian regulator. The model is live and observable; whether it is durable is unresolved.

A March 2026 competition authority decision against Opella Healthcare Hungary circulates in GLP-1 discussions as evidence of enforcement against weight-loss drug marketing. It is not. The GVH proceeding concerned misleading claims about a probiotic product, and has no GLP-1 subject matter.

This page records it because the misattribution is common and because it matters for how the advertising risk in Hungary is assessed. The correct reading is that GVH is active and willing to fine in the consumer-health space, so the general risk of unfair-commercial-practice exposure is real, but that no dated GLP-1-specific enforcement action in Hungary was found. That is a different and weaker claim than the one usually made.

Obesity is not reimbursed in any form. Semaglutide is reimbursed as Ozempic for type 2 diabetes under NEAK rules, with indication conditions and specialist involvement. Wegovy, Saxenda and Mounjaro for weight management are paid in full by the patient.

Hungarian self-pay prices sit at a level that is high relative to median income even when the euro-denominated price is unremarkable, which compresses the addressable market to a relatively narrow urban segment and increases the appeal of both cross-border purchase and compounded or grey-market supply.